Search research articles
Contact Us
Filters
Showing results (951-960 of 990) with videos related to
Page
of 99
Sort By:
Biochemistry
|
November 11, 1999
Zinc-dependent structural stability of human Sonic hedgehog
E S Day, D Wen, E A Garber, et al.
Nature Materials
|
May 3, 2016
Tuning hardness in calcite by incorporation of amino acids
Yi-Yeoun Kim, Joseph D Carloni, Beatrice Demarchi, et al.
Journal of Crohn'S & Colitis
|
July 8, 2016
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease
Elena Dubcenco, Guangyong Zou, Larry Stitt, et al.
Bioconjugate Chemistry
|
January 19, 2006
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model
Darren P Baker, Edward Y Lin, Kochung Lin, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
September 15, 2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis
Darren P Baker, Robert Blake Pepinsky, Margot Brickelmaier, et al.
Multiple Sclerosis and Related Disorders
|
January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years
Ann D Bass, Rafael Arroyo, Aaron L Boster, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
November 12, 2016
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models
Antonio Boccia, Cyrus Virata, Daniel Lindner, et al.
Neurology and Therapy
|
June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
Samuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Biochemistry
|
April 4, 2001
Enhanced potency of human Sonic hedgehog by hydrophobic modification
F R Taylor, D Wen, E A Garber, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Adam Cuker, Ann D Bass, Congor Nadj, et al.
Page
of 99
Search research articles
Search
Showing results (951-960 of 990) with videos related to
Sort By:
Page
of 99
Biochemistry
|
November 11, 1999
Zinc-dependent structural stability of human Sonic hedgehog
E S Day, D Wen, E A Garber, et al.
Nature Materials
|
May 3, 2016
Tuning hardness in calcite by incorporation of amino acids
Yi-Yeoun Kim, Joseph D Carloni, Beatrice Demarchi, et al.
Journal of Crohn'S & Colitis
|
July 8, 2016
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease
Elena Dubcenco, Guangyong Zou, Larry Stitt, et al.
Bioconjugate Chemistry
|
January 19, 2006
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model
Darren P Baker, Edward Y Lin, Kochung Lin, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
September 15, 2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis
Darren P Baker, Robert Blake Pepinsky, Margot Brickelmaier, et al.
Multiple Sclerosis and Related Disorders
|
January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years
Ann D Bass, Rafael Arroyo, Aaron L Boster, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
November 12, 2016
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models
Antonio Boccia, Cyrus Virata, Daniel Lindner, et al.
Neurology and Therapy
|
June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
Samuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Biochemistry
|
April 4, 2001
Enhanced potency of human Sonic hedgehog by hydrophobic modification
F R Taylor, D Wen, E A Garber, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Adam Cuker, Ann D Bass, Congor Nadj, et al.
Page
of 99